Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1440-1797.2009.01244.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Commentary on the 2021 update of the KDIGO clinical practice guideline for management of blood pressure in chronic kidney disease.
Nephrology (Carlton)
January 2025
Forward Thinking Design, Sydney, New South Wales, Australia.
The 2021 KDIGO clinical practice guideline for the management of blood pressure (BP) in chronic kidney disease (CKD) provided significant practice-changing recommendations for the care of both adult and paediatric CKD patients not receiving dialysis. The purpose of this review is to contextualise these recommendations and evaluate their applicability to the Australian and New Zealand context. Key updates presented in this guideline relate to measurement techniques, with a strong recommendation for standardised office BP measurement, as opposed to routine office BP measurement.
View Article and Find Full Text PDFA cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model.
Health Technol Assess
July 2024
Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, the Netherlands.
Background: The CaRi-Heart® device estimates risk of 8-year cardiac death, using a prognostic model, which includes perivascular fat attenuation index, atherosclerotic plaque burden and clinical risk factors.
Objectives: To provide an Early Value Assessment of the potential of CaRi-Heart Risk to be an effective and cost-effective adjunctive investigation for assessment of cardiac risk, in people with stable chest pain/suspected coronary artery disease, undergoing computed tomography coronary angiography. This assessment includes conceptual modelling which explores the structure and evidence about parameters required for model development, but not development of a full executable cost-effectiveness model.
Survival after Surgery among Cholangiocarcinoma Patients Comparing between Mucin Producing and Non-Mucin Producing.
Asian Pac J Cancer Prev
June 2024
Department of Global Health, Research School of Population Health, Australian National University, Canberra, ACT, 2601, Australia.
Background: Mucin-producing cholangiocarcinoma (MPCC) was rare biliary tract malignancy. Studies regarding this type of cholangiocarcinoma (CCA) were limited, particularly the survival outcome. We aim to evaluate the survival rate, median survival time after surgery among CCA patients and to determine the association between MPCC and survival.
View Article and Find Full Text PDFUpdate Thiazide Diuretic Evidence Review for CARI Guidelines Kidney Stones Recommendations.
Kidney Int Rep
May 2024
School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
Management of chronic kidney disease for Māori in Aotearoa New Zealand: a summary of clinical practice guidelines.
N Z Med J
May 2024
Professor, University of Otago, Christchurch, New Zealand; Nephrologist, Te Whatu Ora Waitaha, New Zealand.
Aims: The kaupapa of the Caring for Australians and New Zealanders with Kidney Impairment (CARI) Clinical practice guidelines for management of chronic kidney disease for Māori in Aotearoa New Zealand is to provide whānau-centred and evidence-based recommendations to healthcare systems, healthcare providers and healthcare workers. The guidelines include screening, identification, management and system-level responses to chronic kidney disease (CKD) to deliver best practice care to Māori affected by CKD across community, primary and secondary services.
Methods: The guidelines are funded by the Ministry of Health - Manatū Hauora and are written by a panel of Māori and non-Māori clinicians and literacy experts across Aotearoa New Zealand from Kaupapa Māori organisations, general practice and nephrology units using standardised methods.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!